Literature DB >> 27397043

Pembrolizumab for classical Hodgkin's lymphoma.

Talha Khan Burki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27397043     DOI： 10.1016/S1470-2045(16)30301-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.

Authors:  Hongshan Li; Jingyu Yu; Chao Liu; Jiang Liu; Sriram Subramaniam; Hong Zhao; Gideon M Blumenthal; David C Turner; Claire Li; Malidi Ahamadi; Rik de Greef; Manash Chatterjee; Anna G Kondic; Julie A Stone; Brian P Booth; Patricia Keegan; Atiqur Rahman; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-06-01       Impact factor: 2.745

2.  CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.

Authors:  Boya Deng; Jae-Hyun Park; Lili Ren; Poh Yin Yew; Kazuma Kiyotani; Tatjana Antic; Kelly O'Connor; Peter H O'Donnell; Yusuke Nakamura
Journal:  Cancer Rep (Hoboken)       Date:  2018-04-10

Review 3.  Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.

Authors:  Jun Zhang; L Jeffrey Medeiros; Ken H Young
Journal:  Front Oncol       Date:  2018-09-10       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.